Andrea Lacianca’s Post

In the fast-paced world of biopharma, finding the right patients is crucial—especially when it comes to rare diseases. Traditional claims data analysis has its limitations, but Ambit's Dynamic LeadGen is here to change the game. Dynamic LeadGen is designed to explicitly address rare disease patient finding challenges, setting a new standard in the market, combining transparency, measurable impact, continuous optimization, proactive adaptation, and a client-centric philosophy. Discover how we're reimagining rare disease patient finding and paving the way for a healthier, more equitable future—read our new blog post now: https://hubs.li/Q02xNn1q0 #dynamicleadgen #patientfinding #patientidentification #claimsdata #claimsdatanalysis #ontheblog #blog

// Patient associations/Industry: the key to a positive interaction // What rare disease patients and families want is a simpler life. Discover what makes the relationship between members of a patients’ association and a biotech company work so well in this interview! #kayentis #eCOA #clinicaltrials #raredisease #patientassociation

Developing a therapy for a rare disease is far from standard. @Veristat's scientific experts excel at coordinating the regulatory pathway, patient recruitment, and data collection for such therapies, accounting for 35% of our work. Learn more > https://lnkd.in/eaa7vjqs. #RareDiseaseMonth #RareDisease #UltraRareDisease #Veristat

Recap from #ISCT2024 Roundtable Discussion with Donald B. Kohn and Steve Grossman “Rare Diseases and Patient Access – The Mission and The Challenges”. Top 3 Takeaways: 1. A global repository for data ,gained through research and clinical trials that are not advancing, is ideal to ensure that efforts for rare disease research and drug development are able to be mined for gold. 2. Reclaiming an asset that is not take forward by a partner puts the follow-up burden back on the original IP holder as they seek to partner and further finance trials. 3. Could re-insurance be a solution for broader access of rare disease therapies?

In a recent conversation with Tamsin Ridgwell our Group Business Director, we explored the dynamic realm of rare diseases and precision medicines. With almost 800 new medicines in development, our discussion provided valuable insights into the challenges and successes of launching initiatives in this transformative field, read more here 👇 https://lnkd.in/gV4_Jxsp #rarediseases #precisionmedicine

👌It is time to close the gap between awareness and action! On this Rare Diseases Day, we all can begin a journey to raise the collective voice pushing for change in the rare disease environment. Join us in building a community in which no one feels alone in their battle. ✅ Rare diseases sometimes require patients and researchers to navigate unfamiliar territory. Today, we encourage our worldwide community of high-level specialists, international CROs, and the pharmaceutical sector to work together to find breakthrough solutions. ↪️ Collaboration is essential for discoveries. By uniting our knowledge, resources, and power, we can effect substantial change and guarantee that every condition is noticed. 🤝 Let's boost cross-border cooperation. Tag a colleague or partner in the comments who shares our passion for rare diseases day. Together, we can have a long-term influence. #RareDisease #CollaborateForChange #ClinicalResearch #CRK #CRO #Rare_Disease_Day2024

It is possible for drug discovery and development of new molecules to happen with a collaborative persuasion. The pre-competitive space is actually a public domain that holds great benefit when developing disease pathways. These can be really long or surprisingly short but nonetheless control our patient's response to the world of injury, infection, stress, hunger and fed states. Even more fascinating is what is possible in determining the markers of disease. Interestingly, this shared space that begins with none of the consortium of players seeking individual gain, leads to prognostic or diagnostic indicators that could ultimately help us conduct stratification of patient populations. Here is why this is important, it fuels the pursuit of personalized medicine that answers the question "With my patient's profile, are they likely to benefit from this intervention or should i pursue another?" This gets me especially excited because #CompoundingPharmacy is one of the best expressions of personalized, precision medicine! #IndustrialPharmacy #PrecisionMedicine #PersonalizedMedicine #RegulatoryAffairs #CompoundingSpecialist

Rare disease therapy clinical development presents unique challenges, from regulatory pathway selection to data collection and cleaning. @Veristat's experts specialize in coordinating all aspects of the development process, accounting for 35% of our work. Learn more > https://lnkd.in/gCN59Wew Reach out to learn more! #RareDiseaseMonth #RareDisease #UltraRareDisease #Veristat

NICE consultation on integrated topic prioritisation and strategic principles consultation - MAP response Our Policy & Public Affairs team have prepared a response for the recent NICE consultation on integrated topic prioritisation and strategic principles. We invited members to share their comments on our response to highlight the impact on smaller biopharma companies with a focus on innovative rare disease treatments. In our response, we highlighted how NICE could have more of a strategic focus on rare disease and we have created the quote below to summarise our response.   To find out more about NICE's strategic priorities, the consultation timeline and our response, you can visit: https://lnkd.in/e4sYkNBa   #NICE #ConsultationResponse #policy

Clinical trials are a cornerstone of drug development, but they can't alone capture the many complexities of the lives of patients in an uncontrolled environment. Join our host Kostas Trakas and guest, rare disease patient advocate Joan Paulin, as they dive into the complexities of drug effectiveness beyond clinical trials. Discover what rare diseases can tell us about the importance of post-market surveillance and real-world evidence in painting a complete picture of a drug's impact. Check out the full conversation with Joan here: https://lnkd.in/gxbVFuv3 🌟💬 #DrugDevelopment #ClinicalTrials #RWE #HealthInnovation #RealWorldEvidence